Annual Accounts Payable
$3.80 B
+$1.56 B+69.46%
31 December 2023
Summary:
Novo Nordisk A/S annual accounts payable is currently $3.80 billion, with the most recent change of +$1.56 billion (+69.46%) on 31 December 2023. During the last 3 years, it has risen by +$2.86 billion (+302.33%). NVO annual accounts payable is now at all-time high.NVO Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$3.61 B
-$665.36 M-15.58%
30 September 2024
Summary:
Novo Nordisk A/S quarterly accounts payable is currently $3.61 billion, with the most recent change of -$665.36 million (-15.58%) on 30 September 2024. Over the past year, it has increased by +$759.01 million (+26.65%). NVO quarterly accounts payable is now -15.58% below its all-time high of $4.27 billion, reached on 30 June 2024.NVO Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVO Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +69.5% | +26.6% |
| 3 y3 years | +302.3% | +160.4% |
| 5 y5 years | +267.3% | +317.6% |
NVO Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +302.3% | -15.6% | +259.8% |
| 5 y | 5 years | at high | +302.3% | -15.6% | +357.0% |
| alltime | all time | at high | +4358.6% | -15.6% | +4129.8% |
Novo Nordisk A/S Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $3.61 B(-15.6%) |
| June 2024 | - | $4.27 B(+127.1%) |
| Mar 2024 | - | $1.88 B(-50.5%) |
| Dec 2023 | $3.80 B(+69.5%) | $3.80 B(+33.5%) |
| Sept 2023 | - | $2.85 B(+9.7%) |
| June 2023 | - | $2.60 B(+76.4%) |
| Mar 2023 | - | $1.47 B(-34.4%) |
| Dec 2022 | $2.24 B(+66.1%) | $2.24 B(+104.3%) |
| Sept 2022 | - | $1.10 B(-46.6%) |
| June 2022 | - | $2.06 B(+105.3%) |
| Mar 2022 | - | $1.00 B(-25.8%) |
| Dec 2021 | $1.35 B(+42.9%) | $1.35 B(-2.5%) |
| Sept 2021 | - | $1.38 B(+13.6%) |
| June 2021 | - | $1.22 B(+13.7%) |
| Mar 2021 | - | $1.07 B(+13.4%) |
| Dec 2020 | $944.93 M(-0.9%) | $944.93 M(-2.1%) |
| Sept 2020 | - | $965.44 M(-28.6%) |
| June 2020 | - | $1.35 B(+71.3%) |
| Mar 2020 | - | $789.23 M(-17.2%) |
| Dec 2019 | $953.20 M(-7.9%) | $953.20 M(+10.4%) |
| Sept 2019 | - | $863.71 M(+7.6%) |
| June 2019 | - | $802.70 M(+26.5%) |
| Mar 2019 | - | $634.48 M(-38.7%) |
| Dec 2018 | $1.03 B(+14.5%) | $1.03 B(+37.3%) |
| Sept 2018 | - | $753.99 M(-16.6%) |
| June 2018 | - | $904.35 M(+32.9%) |
| Mar 2018 | - | $680.62 M(-24.7%) |
| Dec 2017 | $904.05 M(+5.8%) | $904.05 M(+26.1%) |
| Sept 2017 | - | $717.01 M(+9.5%) |
| June 2017 | - | $654.85 M(+20.5%) |
| Mar 2017 | - | $543.28 M(-36.4%) |
| Dec 2016 | $854.82 M(+18.4%) | $854.82 M(+27.3%) |
| Sept 2016 | - | $671.53 M(-15.8%) |
| June 2016 | - | $797.39 M(+40.2%) |
| Mar 2016 | - | $568.63 M(-21.2%) |
| Dec 2015 | $721.71 M(-10.7%) | $721.71 M(+24.4%) |
| Sept 2015 | - | $579.98 M(-1.9%) |
| June 2015 | - | $591.10 M(+1.6%) |
| Mar 2015 | - | $581.91 M(-28.0%) |
| Dec 2014 | $808.19 M(+6.7%) | $808.19 M(+58.7%) |
| Sept 2014 | - | $509.33 M(-6.8%) |
| June 2014 | - | $546.65 M(-14.9%) |
| Mar 2014 | - | $642.61 M(-15.2%) |
| Dec 2013 | $757.39 M(+10.7%) | $757.39 M(+42.8%) |
| Sept 2013 | - | $530.31 M(+4.6%) |
| June 2013 | - | $506.89 M(-4.2%) |
| Mar 2013 | - | $529.19 M(-22.6%) |
| Dec 2012 | $683.97 M | $683.97 M(+46.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2012 | - | $465.60 M(+5.3%) |
| June 2012 | - | $442.17 M(-3.5%) |
| Mar 2012 | - | $458.11 M(-20.1%) |
| Dec 2011 | $573.49 M(+10.6%) | $573.49 M(+36.6%) |
| Sept 2011 | - | $419.77 M(-18.7%) |
| June 2011 | - | $516.59 M(-3.3%) |
| Mar 2011 | - | $534.18 M(+3.0%) |
| Dec 2010 | $518.40 M(+20.2%) | $518.40 M(+41.4%) |
| Sept 2010 | - | $366.51 M(-5.2%) |
| June 2010 | - | $386.57 M(+8.8%) |
| Mar 2010 | - | $355.36 M(-17.6%) |
| Dec 2009 | $431.23 M(+0.6%) | $431.23 M(+42.6%) |
| Sept 2009 | - | $302.40 M(-3.3%) |
| June 2009 | - | $312.88 M(+0.9%) |
| Mar 2009 | - | $310.03 M(-27.7%) |
| Dec 2008 | $428.64 M(+12.5%) | $428.64 M(+49.3%) |
| Sept 2008 | - | $287.07 M(-15.6%) |
| June 2008 | - | $340.19 M(+2.7%) |
| Mar 2008 | - | $331.09 M(-13.1%) |
| Dec 2007 | $381.04 M(+25.8%) | $381.04 M(+31.9%) |
| Sept 2007 | - | $288.84 M(-0.4%) |
| June 2007 | - | $290.00 M(+7.4%) |
| Mar 2007 | - | $270.00 M(-10.8%) |
| Dec 2006 | $302.82 M(+27.2%) | $302.82 M(+54.5%) |
| Sept 2006 | - | $196.00 M(-7.9%) |
| June 2006 | - | $212.82 M(-6.6%) |
| Mar 2006 | - | $227.75 M(-4.3%) |
| Dec 2005 | $238.00 M(+22.2%) | $238.00 M(+48.8%) |
| Sept 2005 | - | $159.91 M(-17.0%) |
| June 2005 | - | $192.72 M(+8.2%) |
| Mar 2005 | - | $178.10 M(-8.6%) |
| Dec 2004 | $194.81 M(+13.9%) | $194.81 M(+58.3%) |
| Sept 2004 | - | $123.03 M(-7.4%) |
| June 2004 | - | $132.85 M(+15.6%) |
| Mar 2004 | - | $114.92 M(-32.8%) |
| Dec 2003 | $171.01 M(+40.3%) | $171.01 M(+40.3%) |
| Dec 2002 | $121.89 M(+6.1%) | $121.89 M(+6.1%) |
| Dec 2001 | $114.84 M(-5.9%) | $114.84 M(-5.9%) |
| Dec 2000 | $122.01 M(+12.2%) | $122.01 M(+12.2%) |
| Dec 1999 | $108.76 M(-9.9%) | $108.76 M(-9.9%) |
| Dec 1998 | $120.71 M(+41.6%) | $120.71 M(+41.6%) |
| Dec 1997 | $85.27 M(-35.2%) | $85.27 M(-35.2%) |
| Dec 1996 | $131.50 M(-73.2%) | $131.50 M(-73.2%) |
| Dec 1995 | $490.40 M(+189.8%) | $490.40 M(+189.8%) |
| Dec 1994 | $169.24 M(+23.6%) | $169.24 M(+23.6%) |
| Dec 1993 | $136.90 M(-60.2%) | $136.90 M(-60.2%) |
| Dec 1992 | $344.33 M(+175.2%) | $344.33 M(+175.2%) |
| Dec 1991 | $125.10 M(+10.7%) | $125.10 M(+10.7%) |
| Dec 1990 | $112.98 M | $112.98 M |
FAQ
- What is Novo Nordisk A/S annual accounts payable?
- What is the all time high annual accounts payable for Novo Nordisk A/S?
- What is Novo Nordisk A/S annual accounts payable year-on-year change?
- What is Novo Nordisk A/S quarterly accounts payable?
- What is the all time high quarterly accounts payable for Novo Nordisk A/S?
- What is Novo Nordisk A/S quarterly accounts payable year-on-year change?
What is Novo Nordisk A/S annual accounts payable?
The current annual accounts payable of NVO is $3.80 B
What is the all time high annual accounts payable for Novo Nordisk A/S?
Novo Nordisk A/S all-time high annual accounts payable is $3.80 B
What is Novo Nordisk A/S annual accounts payable year-on-year change?
Over the past year, NVO annual accounts payable has changed by +$1.56 B (+69.46%)
What is Novo Nordisk A/S quarterly accounts payable?
The current quarterly accounts payable of NVO is $3.61 B
What is the all time high quarterly accounts payable for Novo Nordisk A/S?
Novo Nordisk A/S all-time high quarterly accounts payable is $4.27 B
What is Novo Nordisk A/S quarterly accounts payable year-on-year change?
Over the past year, NVO quarterly accounts payable has changed by +$759.01 M (+26.65%)